Key facts
- CHIGENOVO’s last known valuation is $110.4M (Mar 2022).
- It has raised $41.0M; the latest was Later Stage VC in Sep 2025.
- Notable investors include Cowin Capital, Puhua Capital, Lapam Capital, Lotus Lake Ventures, Huayi Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for CHIGENOVO
- ·The full record, as it builds
Funding rounds
No funding rounds for CHIGENOVO are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About CHIGENOVO
Developer of clinical genetic diagnosis, fertility prevention and gene therapy drug for hereditary eye diseases. The company specializes in developing ophthalmic gene therapy drugs backed by accurate gene diagnosis, providing reliable ophthalmic gene pharmaceuticals for the public.
- Sector
- Healthcare
- HQ
- Beijing, China
- Founded
- 2016
- Website
- chinagene.cc/
- Ownership
- Privately Held (backing)
CHIGENOVO doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CHIGENOVO shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CHIGENOVO in its N-PORT filings yet. We sweep new filings monthly.